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Abstract
Background: Cardiovascular risk management plays an important role in primary care. In patients at high risk for
cardiovascular diseases (CVD) lifestyle and, where appropriate, medical interventions are recommended in guidelines.
Health-related quality of life (HRQoL) is an important outcome in clinical practice. This study aimed to assess the HRQoL of
this patient group and to investigate the impact of both patients’ characteristics and practice quality scores on their
assessments of HRQoL.
Methods and Findings: An observational study in 218 general practices from 8 European countries was conducted. 2142
patients at risk for CVD (33.5% female) with a mean age of 66.3 (SD 9.1) years completed a questionnaire including the EQ-
5D instrument and provided data from medical record. Validated quality indicators of general practices were assessed using
practice questionnaires and face-to-face interviews. A hierarchical multilevel analysis was performed to identify predictors of
EQ-5D scores at patient and practice level. The mean EQ-5D score was 0.78 (SD 0.19). Female gender (r=20.03, p,0.0016),
age (r=20.01, p=0.0387) and lower educational level (r=20.03, p,0.0001) were correlated negatively with EQ-5D scores.
Clinically more important was the correlation of HRQoL with the frequency of practice contacts (r=20.12, p,0.0001) and
the number of uncontrolled risk factors (r=20.01, p,0.0039). Medication adherence (r=0.032, p,0.0001), and physical
activity (r=0.02, p,0.0001) were identified as positive predictors of HRQoL. The EUPROPEP-score category ‘organization’
(r=0.02, p,0.0001) was positively related to EQ-5D scores, whereas other practice scores were not correlated to EQ-5D-
scores.
Conclusions: In patients at risk for CVD, good medication adherence, regular physical activity, controlling of biomedical risk
factor levels and patient-centered practice organization have been shown to be positively correlated to HRQoL and should
therefore be targeted in interventions not only to reduce morbidity but also to sustain or even to ameliorate HRQoL.
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Introduction
Cardiovascular disease (CVD) and coronary heart disease
(CHD) are major causes of premature death in Europe and also
important causes of morbidity, contributing substantially to
escalating healthcare costs [1]. CVD is a main contributor to
the almost threefold difference in mortality between adult men and
women in Europe [2]. Cardiovascular risk management (CVRM),
which is mostly provided in primary care, includes counseling on
lifestyle, preventive medication, where appropriate, and continu-
ous monitoring to control modifiable risk factors such as high
blood pressure [3,4]. It has been stated that health services are
predominately oriented towards care rather than prevention and
towards acute rather than chronic care [2].
Previous research has focused on chronic care improvement
resulting in the development of the chronic care model (CCM)
[5,6] that lead to health policy interventions to enhance evidence
based chronic care such as incentivising chronic illness care in the
United Kingdom [7] or the nationwide implementation of disease
management programs in Germany [8]. However, research and
policy efforts to improve risk management of individuals at risk for
chronic diseases were less intensive, although the preventive
impact is more considerable in this group [9].
As CVD develops usually over many years, general practitioners
and general practice teams are in a unique position to provide
continuous advice, support and counseling to patients at risk to
prevent manifestation of CVD in a community setting [10].
Although there is given the opportunity to prevent CVD,
especially in strong primary health care systems, where the
general practitioner is acting as a gatekeeper, it has been shown
that strong primary health care systems are more likely to make
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29334efforts to improve disease management but not necessarily efforts
to improve delivery of lifestyle interventions [11].
HRQoL has gained increased attention as an outcome measure
of interventions and treatments in patients with established
cardiovascular disease [12,13]. For individuals at risk for
developing CVD, HRQoL measurement has been considered
particularly useful because of two major reasons: As these
individuals may be asymptomatic or have only mild symptoms
over a long period of time, morbidity or mortality alone are
insensitive measures of the impact of therapy, whereas HRQoL
outcomes can help select therapeutic options [14]. Secondly, it
may be difficult for these individuals to consider an asymptomatic
illness as serious and to be aware of the benefit of medical
treatment, especially if side effects of drugs may impair their life
satisfaction [15].
There are different instruments available to measure HRQoL
such as the SF-36 questionnaire and the EQ-5D instrument that
has already been widespread used in CVD studies [12]. The EQ-
5D instrument is a validated generic measure of health-related
quality of life that was developed by the EuroQol Group [16] and
it is simply for patients to understand and to complete.
There is a lack of studies that examine HRQoL in individuals at
risk for CVD and also of studies that address predictors of HRQoL
in this group [17]. The knowledge of these predictors may be
useful to tailor interventions to the needs of individuals at risk for
CVD aiming to improve both care and HRQoL. The aim of our
study was therefore to describe HRQoL of individuals at risk for
CVD in European primary care settings using the EQ-5D
instrument and to identify predictors that have an impact on
EQ-5D scores at patient and practice level.
Methods
This study is part of the European Practice assessment (EPA) -
Cardio project, focusing on the assessment of cardiovascular
prevention and management in European primary care. In the
first stage of the 4-year EPA-Cardio project (January 2006) we
developed quality indicators to measure cardiovascular care [18]
and identified additional instrument measures [19] including the
EQ-5D for use in a subsequent observational study. The
international cross-sectional observational study was conducted
in 10 European countries between 2008 and 2009, i.e. Austria,
Belgium, France, Finland, Germany, the Netherlands, Slovenia,
Spain, Switzerland and the United Kingdom. In this part of the
study Spain was excluded because only data from medical records
were collected and Finland due to insufficient data quality. Israel
was only involved in the practice survey (Figure 1). Ethics
committees of all participating countries approved the study.
Full details of the study design and data collection methods have
been published elsewhere [19,20]. In summary, general practices
were approached by the national research teams aiming to include
a representative sample of 36 practices per country. Random
samples of 30 patients at high risk for CVD per practice where
identified from medical records according to the criteria listed in
Table 1 and asked for participation, in order to receive informed
written consent from at least 15 patients per practice (50%
response).
Measures
Patients were posted a questionnaire including demographic
items (e.g. age, gender, education and marital status) and six
validated survey instruments: These were 1) the ‘Rapid Assessment
of Physical Activity (RAPA)’ [21], 2) the ‘Rapid Eating and
Activity Assessment for Participants-Short Version (REAP-S) [22],
3) the ‘Mid-Sized model - baseline measurements for smoking
[23], and 4) the 4-item Morisky-questionnaire to assess, where
appropriate, medication adherence [24]. The questionnaire also
included 5) the EUROPEP-instrument to evaluate general
practice care [25], and 6) the EQ-5D instrument, that generates
a single index score. It is based on a descriptive system that defines
Figure 1. Data flowchart.
doi:10.1371/journal.pone.0029334.g001
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activities’, ‘pain/discomfort’ and ‘anxiety/depression’. The EQ-
5D score has a range from 0 to 1(full health) and is calculated by
applying scores from the EQ-5D preference weights elicited from
the general population. For this study, the EQ-5D score was
calculated using the value set for the European population [26,27].
Additionally, patient data from medical records were collated
using a paper based audit abstraction tool that included levels of
blood pressure, cholesterol, body mass index (BMI) etc.
Researchers collated practice data by posting questionnaires
and by face to face interviews with general practitioners using
standardized interview guides. These instruments contained
questions to characterize the practice according to size, location
or number and function of practice staff. Quality indicators (QI)
that were developed during the EPA-Cardio project [18] and
derived from the EPA practice-management instrument [28] were
converted into questions for the practice team. The quality
indicators represented CVD care aspects (33 QI) [18] and
organizational aspects of the practice management in the 3
dimensions ‘information process and technology’(11 QI), ‘organi-
zation of chronic care and prevention’ (19 QI) and ‘quality
improvement’ (13 QI) [28]. All measures were piloted before being
used in the study [19].
Analyses
The main outcome measure was the EQ-5D score. To score
practice quality indicators we aggregated the items of the practice
questionnaires using the homogeneity analysis by alternating least
squares (HOMALS). With this analysis, we identified 32 binary
items with discrimination measures over 0.4 in two dimensions
‘‘practice quality management’’ (15 items) and ‘‘practice CVD
care’’ (17 items) (Appendix S1). Scores were calculated by
summing up the number of ‘yes’- answers resulting in a range
from 0 to 15 for the quality-management score and from 0 to 17
for the CVD-care score.
Because of the hierarchical structure of the data, multilevel
analysis was applied, which takes into account the dependence
between patient outcomes (level 1) within primary care practices
(level 2) nested within countries (level 3). Several models were
evaluated treating practice and country levels as random effects
and allowing explanatory variables at different levels (for details,
see Table 2). The multilevel analysis started with an intercept-only
(null) model for the three-level data without any predictor
variables. Variance partition coefficients in each level were
calculated using the restricted maximum likelihood (REML)
method. The corresponding intra-class correlations (ICC) [29] at
the practice and country level were provided. The next model
included only the patient-level predictors as fixed effects. Finally,
predictor variables on both patient and practice level were added
as fixed effects. Explanatory variables on country level were not
examined. In the final model adjusted for all variables, we
included a total set of 13 potential explanatory variables, 11 on
patient level and 2 on practice level (Table 2). The coefficients of
the final model indicate the relation between the EQ-5D score and
each explanatory variable. The differences between the ‘‘null’’-
model and the final adjusted model show to which extend the
explanatory variables explain the variation in the outcome. Only
patients for whose data on all explanatory variables on the
different levels were available could be included in the final model.
A non-responder analysis was performed between those patients
included in the final dataset and those not included because of
non-responding the EQ-5D items or other missing data. The
significance level was set to 5% (two-sided). Regression coefficients
and corresponding two-sided 95% confidence intervals (CI) were
calculated and considered statistically significant if the CI excluded
zero. All statistical analyses were carried out by using SPSS version
18.0 (SPSS Inc., Chicago, IL, USA). The multilevel analyses were
conducted by using the procedure PROC MIXED in SAS version
9.2 (SAS Institute, Cary, NC).
Results
Demographics and practice characteristics
For 2802 individuals at high risk for CVD we were able to
match data from medical records and survey instruments from 218
primary care practices in 8 European countries: Austria, Belgium,
France, Germany, the Netherlands, Slovenia, Switzerland and the
UK (Figure 1).
For 2554 individuals (91.1%) EQ-5D scores could be calculated.
As we intended to examine the influence on medication adherence
on EQ-5D scores we included only those patients who reported to
take medication regularly reducing the number of included
patients to 2318 (90.8% of responders). The sample size was
reduced again due to missing data in the final multilevel
hierarchical regression model with 13 potential explanatory
variables to 2142. A non-responder analysis showed that excluded
patients were similar to those included in most characteristics with
exception of the following: They had less frequent practice
contacts, were to a greater proportion smoker, and to a smaller
proportion obese (BMI$30) and had a slightly lower ‘‘healthy-
diet’’ score. Furthermore, excluded individuals had higher
EUROPEP scores. On average, 33.5% of the finally included
patients were female and the mean age was 66.3 years. (SD 9.1).
Most patients (79.0%) were married or cohabiting and had been in
school for more than 9 years (68.3%). (Table 3)
In terms of risk factors, the majority of patients had increased
levels for blood pressure, total cholesterol and blood glucose.
Furthermore 23.0% were smokers and a third had a BMI of 30 or
above. Half of the patients were underactive, defined as regular
moderate (vigorous) physical activity less than 150 (60) min/week.
The ‘healthy-diet’-score (maximum=3 on a 3-point likert scale)
Table 1. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
1. High- risk patients defined by risk calculation with recommended tools
according to national guidelines, e.g. 10% fatal CVD risk as calculated by the
Dutch risk tables
or
2. Proxy measure: Patients with three out of the following four risk factors:
hypertension, hyperlipidemia, smoking, men over 60 years
1. Patients with established CVD (including ischemic heart disease, myocardial
infarction, angina pectoris, coronary surgery or revascularisation procedures,
ischaemic stroke, transient ischemic attack, claudication or peripheral vascular
disease)
2. Patients with diabetes
3. Terminal illness, cognitive disorders (e.g. dementia), psychiatric diseases (e.g.
schizophrenia) and lack of language knowledge
doi:10.1371/journal.pone.0029334.t001
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evaluation of general practice care were over 4 on a 5-point likert
scale ranging from 1(poor) to 5 (excellent), the subscale score
‘clinical behavior’ (4.50) was slightly higher than the subscale score
‘organization of care’ (4.46).
The included practices were mainly located in towns with less
than 100,000 inhabitants with 2 full time equivalents (FTE) GPs
and 1.5 FTE nurses in average. The 3 excluded practices showed
no differences in relation to these characteristics. Means of
practice quality-scores were 8.3 (SD 3.62) for quality management
(range 0–15) and 8.19 (SD 4.41) for CVD care (range 0–17).
EQ-5D scores and predictors of EQ-5D levels
The overall mean EQ-5D score was 0.78 (SD 0.19). In the
multilevel analyses the intercept-only model showed that the
greatest proportion of variance in EQ-5D scores occurred at the
patient level (92.3%). The proportion of variance (intra-class
coefficients -ICC) at practice level was estimated to 2.7%, .the
proportion of variance at practice level was estimated to 5.0%.
Including explanatory patient variables into the model resulted
in smaller variance proportions, meaning that these variables
explained the variance. Additional including of explanatory
practice variables resulted in the final adjusted model that
explained the variance at the country level to 23%, at the practice
level to 50% and the variance at the patient level plus random to
14%. Table 4 provides details of the relationship between the
explanatory variables on patient and practice levels respectively
and the EQ-5D scores. Adjusted for all other variables, regression
coefficients indicate the changes of the EQ-5D score in
comparison to a baseline category for categorical variables or
with one unit increase of a continuous variable. At patient level,
EQ-5D index scores of female patients were lower compared to
male patients (r=20.03; p=0.0016). Each 5-year increase in age
was associated with a 0.01 decrease in EQ-5D scores (r=20.01;
p=0.0387). Patients with a lower educational level scored HRQoL
lower than higher educated individuals (r=20.03; p,0.0001).
Each uncontrolled risk factor (e.g. mean blood pressure level over
140/90) was associated with a 0.01 decrease in EQ-5D scores
(r=20.01; p=0.0039) resulting in a maximum difference of 0.05
between patients with zero and five uncontrolled risk factors. Each
increase of one point of the ‘‘Morisky score’’ (0–4) indicating
medication adherence was linked to a 0.02 increase of EQ-5D
scores (r=0.02; p,0.0001) resulting in a maximum increase of
0.08 (460.02) for the highest score (4) compared with the lowest
one (0). Increasing physical activity levels were related to higher
ratings of HRQoL (r=0.02; p,0.0001) with a 0.02 increase of
EQ-5D scores per unit.
Married or cohabiting individuals had higher EQ-5D scores
than singles but this relationship was not significant (r=20.03;
p=0.5741). Although patients’ evaluation of organizational
aspects of practice care (EUROPEP score ‘organization of care’)
was linked markedly and significantly (r=0.02; p,0.0001)t o
HRQoL, namely 0.02 increase of EQ-5D scores with one
increasing unit of the EUROPEP score (0–7), quality scores of
general practice performance were not significantly associated.
(Table 4).
Discussion
Our study has 3 main findings: Firstly, health-related quality of
life (HRQoL) is impaired in patients at risk for cardiovascular
diseases. Secondly, HRQoL is correlated to patient characteristics
with limited practical relevance. The third and most clinically
important finding is that we identified positive predictors of
HRQoL; namely good medication adherence, regular physical
activity, control of modifiable risk factor levels and providing
patient-centered organizational practice support. These predictors
have also substantial scope to reduce morbidity and mortality and
should therefore be focused in efforts to improve prevention of
CVD.
Relating to our first result, the mean EQ-5D score was 0.78 for
individuals at risk for CVD. It has been shown that this level is in
line with findings from other CVD-studies describing similar
Table 2. Explanatory variables included in the multilevel analysis.
Variables Categories/Scoring
Level 1: patient
Gender 2 categories: female; male
Age Continuous: age divided by 5
Education Years in school; 2 categories : #9 years; .9 years
Marital status 2 categories: married/cohabitating; single/separated/divorced/widowed
Frequency of practice attendance Practice attendance within 12 months; 3 categories: up to 3 times/year; 4–7 times/
year; more than 7 times/year
Medication adherence Continuous sum score (Morisky- 4 items): 0–4 (best)
Physical activity Continuous sum score (RAPA - 9 items): 1 (sedentary) -5 (regularly active)
Healthy diet Continuous (REAP-S - 10 items:): mean: 1–3 (best)
Number of uncontrolled risk factors Continuous sum score: 0–5: 1. mean RR .140/90 mmHg; 2. total cholesterol
.5 mmol/l; 3. blood glucose (fasting.6.1 mmol/l or random .10 mmol/l); 4.
BMI.30; 5. smoking
Patients’ evaluation of practice care ‘‘clinical’’ Continuous: (EUROPEP dimension ‘clinical behavior’ 16 items) mean: 1–5 (best)
Patients’ evaluation of practice care ‘‘organizational’’ Continuous: (EUROPEP dimension ‘organization of care ‘7 items) mean: 1–5 (best):
Level 2: practice
Quality-management score Continuous: sum score of ‘yes-answers’; range:0–15
CVD-care score Continuous: sum score of ‘yes-answers’; range:0–17
doi:10.1371/journal.pone.0029334.t002
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scores for CHD-patients in mild disease stages in comparison to
lower scores (0.51) for CHD-patients in severe disease states [12].
Regarding socio-demographic predictors of the health-related
quality of life, we found a negative relationship between patient
characteristics, such as female gender, increasing age and lower
educational level, and HRQoL. These findings were also reported
in patients with established CVD in previous research [17,30–34].
In terms of the practical impact of our study results, most variables
at the patient level reached statistical significance in the final 3-
level model, but because of the large sample size in our study, we
should also consider what is clinically relevant. Earlier studies on
clinically relevant differences using EQ-5D index score defined a
mean minimally important difference for the EQ-5D of 0.074
(range: 0.011–0.140) [35]. This means that the two categorical
variables gender and educational level with regression coefficients
(r) of 0.03 might be less clinically important. The relationship
between the continuous variable ‘‘age’’ has to be interpreted as
changes in the EQ-5D index scores of 20.01 per unit (5 years),
meaning that only a difference of 35 years in age (765) is related to
a clinically important difference of HRQoL, as measured by a
difference in EQ-5D index scores of 0.07. These findings indicate
that only large differences in age are negatively correlated with
HRQoL and that smaller differences in age (e.g. between 40–50
years) are not clinically important correlated with impaired
HRQoL.
A more clinically important positive predictor of HRQoL was
physical activity. In our study, increasing physical activity ranging
from sedentary (0) up to a regular moderate (vigorous) physical
activity of at least 150 (60) min per week (5) was significantly
associated with increased EQ-5D levels in individuals at risk for
CVD. As the RAPA instrument defines 5 degrees of physical
activity, the r of 0.02 indicates that there is a maximum increase of
0.1 (560.02) comparing EQ-5D index levels of sedentary
Table 3. Patient characteristics (n=2802).
included (n=2142) not included (n=660) P*
Age (years); mean (SD) 66.27 (9.07) 66.13 (9,82) 0,739
Gender 0.925
Female % (n) 33.5 717 33.2 219
Male % (n) 66.5 1425 66.8 441
Marital status 0.372
Single, separated, divorced, widowed % (n) 21.0 (450) 22.7 (139)
Married, cohabited % (n) 79.0 (1692) 77.3 (474)
Education 0.099
,=9 years % (n) 31.7 (680) 35.5 (205)
.9 years % (n) 68.3 (1462) 64.5 (373)
Frequency of practice attendance 0.000
,=3 times/year % (n) 34.1 (731) 48.0 (294)
4–7 times/year % (n) 49.2 (1053) 36.7 (222)
.7 times/year % (n) 16.7 (358) 15.7 (96)
CVD risk factors
RR .140/90 mmHg % (n) 50.9 (1036) 51.0 (346) 1.000
Cholesterol total .=5 mmol/l % (n) 64.8 (1186) 69.2 (368) 0.062
Blood glucose fasting .6.1 or random .10.0
mmo/l % (n)****
14.9 249) 16.5 (84) 0.399
Smoker % (n) 23,0 (387) 33.1 (171) 0.000
BMI .=30% (n) 31.0 (657) 28.2 (181) 0.020
Number of uncontrolled risk factors mean (SD) 1.64 (1.02) 1.68 (0.99) 0.367
Lifestyle
Healthy diet** mean (SD) 2.25 (0.36) 2.18 (0.39) 0.000
Regular moderate physical activity % (n) 48.7 (1043) 53.0 (277) 0.058
Medication adherence (Morisky score=4) % (n) 60.0 (1285) 54.8 (205) 0.174
EUROPEP***
Clinical behaviour; mean (SD) 4.50 (0.60) 4.59 (0.63) 0.003
Organisation of care; mean (SD) 4.46 (0.64) 4.52 (0.66) 0.030
EQ-5D mean (SD) 0.78 (0.19) 0.78 (0.20) 0.688
*p values are based on x
2 tests for categorical variables and on t tests for continuous variables.
**Maximum (best)=3.
***Maximum (best)=5.
****Although patients who were recorded as having diabetes were excluded, we asked to record blood glucose levels, because blood glucose measurementi s
recommend in guidelines for this patient group [3,4].
doi:10.1371/journal.pone.0029334.t003
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as a clinically important amelioration of HRQoL. A positive
relationship between physical activity and HRQoL was also found
in previous research for both populations with established diseases
[36] and general adults [37]. Sedentary lifestyle has been reported
as to be the most prevalent risk factor [38,39]. Persons older than
60 years appear to benefit from exercise training at least as much
as younger adults, and regular physical activity can reduce the risk
of CHD and extend the active lifespan [40]. Additionally it is
reported that lifestyle interventions especially on physical activity
ameliorate HRQoL [31].
Therapeutic encouragement of regular physical activity should
therefore be a major aim in the prevention of CVD, especially in
groups of high risk patients.
The number of uncontrolled (not achieving treatment goals) risk
factors (RR mean .140/90, cholesterol total .5 mmol/l, blood
glucose .6.1 mmol - fasting or .10 mmol-random, BMI.30 and
smoking) were associated with impaired HRQoL in our study. The
r of 20.01 indicates, however, that this relationship may be weaker
than the relationship between physical activity and HRQoL: In
comparison, HRQoL of individuals with uncontrolled levels of risk
factors (RR, cholesterol, blood glucose) who were obese and
smokers, was only impaired minimally (decrease of 0.05 in EQ-5D
levels) compared with individuals without any of these risk factors
number. From the view of GPs, it is desirable that better risk factor
control is associated with improved HRQoL. From the patient
perspective, however, these risk factors are normally asymptomatic
or they feel even worse under treatment [14]. Medical treatment
can be accompanied by side-effects of drugs that may impair life
satisfaction [15].
Previous studies have shown that risk factors among individuals
at risk for CVD are poorly controlled [41]. For practical reasons, it
Table 4. Parameter estimates of the final multilevel model with overall EQ-5D score as dependent variable (N=2142 patients. 215
practices. 8 countries).
Regression
coefficient Standard error 95% confidence intervals P value
PATIENT CHARACTERISTICS
Age
Continuous (5-year units) 20.01 0.00 [20.02; 20.00] 0.0387
Gender
Female 20.03 0.01 [20.05; 20.01] 0.0016
Male Reference
Education. Years in school
,9 years 20.03 0.01 [20.04; 20.02] ,0.001
.9 years Reference
Marital status
Married, cohabitating 20.01 0.02 [20.04; 0.02] 0.5741
Single, separated, widowed Reference
Frequency of practice attendance
Up to 3 times per year 0.12 0.02 [0.08; 0.15] ,0.001
4–7 times per year 0.06 0.01 [0.04; 0.09] ,0.001
more than 7 times per year s Reference
Medication adherence (Morisky)
Continuous 0.02 0.00 [0.01; 0.03] ,0.001
Physical activity status
Continuous 0.02 0.00 [0.01; 0.03] ,0.001
Healthy diet (score)
Continuous 0.02 0.01 [20.00; 0.03] 0.0960
Number of uncontrolled risk factors
Continuous 20.01 0.00 (20.01; 20.00] 0.0039
EUROPEP score ‘clinical behavior’
Continuous 0.01 0.01 [20.01; 0.02) 0. 2199
EUROPEP score ‘organization of care’
Continuous 0.02 0.00 [0.02; 0.03] ,0.001
PRACTICE CHARACTERISTICS
Practice quality management
Continuous 0.00 0.00 [20.00; 0.00] 0.0904
Practice CVD care
Continuous 0.00 0.00 [20.00; 0.00] 0.6529
doi:10.1371/journal.pone.0029334.t004
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treatment to prevent poor medication adherence due to side effects
and impaired HRQoL. The positive relationship between risk
factor control and HRQoL that was found in our study shows that
it is possible to control risk factor levels without impairing
HRQoL. Our findings rather suggest that it is possible not only to
reduce morbidity but also to improve HRQoL slightly by
controlling risk factors.
This result resonates with an additional result of our study,
namely that increasing medication adherence (Morisky score) was
associated with higher EQ-5D scores. This result can also be
regarded not only as statistically but also as practically significant,
as there is a 0.08 difference in EQ-5D index scores between the
lowest degree of the Morisky score indicating poor medication
adherence, and the highest score indicating best medication
adherence. A recently published study reported a positive impact
of HRQoL on medication adherence in hypertensive adults over
65years [42]. The direction of this relationship remains unclear
und might be investigated in further research, but it seems that
HRQoL and medication adherence are correlated positively in
both directions.
It has been stated to consider medication nonadherence as an
unrecognized cardiovascular risk factor [43] and it has been
reported that nonadherence is associated with increased risk for all
cause mortality, cardiovascular mortality and also with cardiac-
specific outcomes, such as hospitalization, heart failure and
coronary revascularization procedures, in patients with CHD
[44]. This may channel the focus on strategies to promote
medication adherence, such as continuous monitoring, decreasing
dose frequency, motivational approaches or combined strategies
[45,46] especially in patients at high risk for CVD who normally
require lifelong treatment and support [47].
The frequency of practice contacts per year was also related to
lower EQ-5D scores in our study. There is a clinically important
relationship between the frequency of practice consultations and
HRQoL. The HRQoL of patients attending the practice (GP) only
up to 3 times a year (EQ-5D index score 0.12 greater), or more
frequently up to 7 times a year (EQ-5D index score 0.06 greater) is
improved compared to patients visiting the practice more than 7
times a year. The frequency of practice contacts per year may also
reflect the severity of disease and be therefore associated with
lower EQ-5D scores [12].
Practice quality indicators u in our study did not show any
statistically or clinically significant associations with patients’
HRQoL in patients at risk for CVD. Maybe, other indicators
relating to the personal interaction between GP and patient or
service aspects would have been more suitable to reflect preventive
care in this patient group.
However, it was possible in our study to show the impact of
practices’ organizational management on patients’ HRQoL
regarding predictors that were assessed at the patient level to
assess satisfaction with care, as the variables included at this level
explained 48.1% of the variance at the practice level: One part of
the EUROPEP instrument (7 items) evaluates patients’ satisfaction
with organizational aspects of care, such as waiting times,
helpfulness of the practice staff, ability to speak the GP on the
phone etc. The regression coefficient, calculated in the multilevel
analysis, indicates a 0.02 increase of EQ-5D scores with each unit
increase of the organizational score of the EUROPEP instrument.
This means a possible maximum increase of EQ-5D scores by 0.14
(0.0267). This result identifies patient-centered organizational
aspects of practice management as clinically significant positive
predictors of HRQoL.
Strengths and limitations
The EPA cardio study is one of the largest international studies
on the management of cardiovascular prevention in European
primary care [20]. We used multilevel modeling to identify
predictors of health-related quality of life in one model adjusting
for all other variables. Hierarchical models combine information
across units to produce accurate and well calibrated prediction of
outcomes [48]. This analytic approach has been seen to be very
relevant in health services research as patients’ data were similarly
clustered at more than one level [49]. We used validated measures
and collected morbidity data from medical record in contrast to
self reported morbidity indicators that could lead to misclassifica-
tions.
Nevertheless, in some countries it was difficult to enroll 36
practices as intended and different sampling methods were used to
identify individuals at high risk for CVD, i.e. by risk calculation
with recommended instruments or by identifying the presence of
risk factors. In the multilevel analyses, the total number of cases
decreased due to missing data, as we conducted a complete cases
analysis. The EQ-5D instrument showed a ceiling effect with 30%
of people scoring the highest value. As also reported in other
studies, EQ-5D may be less sensitive to describe mild-severity
health levels. However, the EQ-5D instrument is reported to have
a better discrimination capacity for socio-demographic and
morbidity indicators that were focused in our study [50]. Because
of the observational design of our study, the correlations found
cannot be used to attest causal associations.
Conclusions
Our study results suggest that HRQoL, as an important patient
related outcome in patients at risk for CVD is correlated
statistically but less clinically significant with socio-demographic
factors such as age, gender or educational level. Additionally,
healthy behavior, such as regular physical activity and a good
medication adherence, and also organizational aspects of practice
management were identified as clinically important predictors of
improved HRQoL. Controlling of risk factors in asymptomatic
individuals is possible without impairing HRQoL. It seems to be
possible to improve both reducing morbidity and ameliorating
HRQoL by interventions that focus on medication adherence,
treatment of modifiable risk factors and lifestyle counseling,
especially to increase physical activity. Patient-centered organiza-
tion of practice management may also play an important role for
ameliorating HRQoL of patients at risk for CVD. On the other
hand, it seems to be important that medical or behavioral
treatment to control risk factors in asymptomatic individuals,
which require lifelong treatment and counseling, should be careful
to address patients’ HRQoL to prevent poor treatment adherence
due to impaired HRQoL. Research and policy might focus on the
development and implementation of ‘‘risk management pro-
grams’’ including these key elements to prevent CVD more
effectively.
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